Dyne Therapeutics and Eikon Therapeutics announce corporate updates

biopharmaceutical executive appointment investor conferences drug discovery neuromuscular diseases

Dyne Therapeutics has announced its participation in several upcoming investor conferences in September 2026. The company's management is scheduled to hold fireside chats at the Cantor Global Healthcare Conference on September 11, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, and the Baird 2026 Global Healthcare Conference on September 15.

Separately, Eikon Therapeutics has appointed Ching-Pin Chang, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Chang, a physician-scientist with over two decades of experience in academic medicine and drug discovery, joins Eikon from Bristol Myers Squibb, where he served as Vice President, Head of Cardiovascular Discovery Biology and Translational Pharmacology.

Entities

Bristol Myers Squibb

Sources

Dyne Therapeutics to Participate in Upcoming Investor Conferences [www.globenewswire.com]

13 days ago

Eikon Therapeutics Appoints Ching-Pin Chang, M. D. , Ph. D. as Executive Vice President and Chief Scientific Officer - Eikon Therapeutics [www.eikontx.com]

11 days ago